


This listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims

Claims 1-8 (cancelled)

Claim 9 (Currently Amended) A method of treating a neoplastic condition or toxicity ~~in a subject~~ associated with an alteration in sphingolipid metabolism in a subject suffering from such disorder comprising administering to the subject an effective amount of a fumonisin or a fumonisin analog thereof of the formula:



wherein the spacer group is selected from the group consisting of alkyl (straight chain or branched, C₁ - C₂₀), hydroxyalkyl (straight chain or branched, C₁ - C₂₀) or and dihydroxyalkyl (straight chain or branched, C₁ - C₂₀); Z is selected from the group consisting of H, O, NH, NQ, NQC(O), NHC(O), CO₂, C(O)NH, and C(O)NQ, wherein Q is an alkyl (straight chain or branched, C₁ - C₆); W is selected from the group consisting of no substituent, H, alkyl (straight chain or branched, C₁ - C₆), aryl (phenyl[[,]]) or substituted phenyl ~~such as substitution with alkyl (straight chain or branched, C₁ - C₆) or halo~~, C(O)(CH₂)_nCO₂H (where n= 1 - 6), C(O) (CH₂)_n CW' CO₂ H, where W' is selected independently from H, alkyl (straight chain or branched, C₁ - C₆), aryl (phenyl[[,]]) or substituted phenyl ~~such as substitution with alkyl (straight chain or branched, C₁ - C₆) or halo~~, and (CH₂)_n CO₂ H, wherein n= 1 - 6; X is selected from the group consisting of H, methyl, CH₂OH (and esters thereof), CH₂NQ'₂ (where Q' is selected independently from H, alkyl (straight chain or branched, C₁ - C₂₀), and acyl (C(O)Q" where Q" is an alkyl, straight chain or branched, C₁ - C₂₀)); and V and Y are independently selected from the group consisting of H or OH (and esters thereof) but not fumonisin B1, fumonisin B2, fumonisin B3, fumonisin B4 or AAL toxin.

Claim 10 (cancelled)

Claim 11 (previously presented) The method of Claim 9, wherein Neimann-Picks syndrome or Tay-Sachs disease is treated.

Claim 12 (previously presented) The method of Claim 9, wherein the fumonisin or fumonisin analog is administered in an amount between 5 and 500 mg.

Claim 13 (previously presented) The method of Claim 9, wherein the fumonisin or fumonisin analog is administered in an amount between 25 and 75 mg.

Claim 14 (previously presented) The method of Claim 9, wherein X is CH₂OH or an ester thereof.

Claim 15 (previously presented) The method of Claim 9, wherein the fumonisin analog has a 2-amino-3,5-diol head group.

Claim 16-46 (cancelled)

Claim 47 (previously presented) The method of Claim 9, wherein the neoplastic condition is esophageal cancer.

Claim 48 (previously presented) The method of Claim 9, wherein the subject is a human.

Claim 49 (previously presented) The method of Claim 9, wherein V is hydroxyl.

Claim 50 (previously presented) The method of Claim 9, wherein V is hydrogen and Y is hydrogen.

Claim 51 (previously presented) The method of Claim 9, wherein V is hydroxyl and Y is hydrogen.

Claim 52 (previously presented) The method of Claims 50 or 51, wherein X is methyl.

Claim 53 (previously presented) The method of Claim 9, wherein the spacer group is alkyl, Z is hydrogen and W is no substituent.

Claim 54 (previously presented) The method of Claim 9, wherein Y is hydrogen, V is hydroxyl, Z is hydrogen and the spacer group is C₁- C₂₀.

Claim 55 (previously presented) The method of claim 9, wherein Z is hydrogen.

Claim 56 (previously presented) The method of claim 9, wherein the spacer group is alkyl (straight chain or branched, C₁ - C₂₀).

Claim 57 (previously presented) The method of claim 9, wherein W is no substituent.